| __timestamp | Exelixis, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 7459000 |
| Thursday, January 1, 2015 | 96351000 | 11831000 |
| Friday, January 1, 2016 | 95967000 | 25705000 |
| Sunday, January 1, 2017 | 112171000 | 46181000 |
| Monday, January 1, 2018 | 182257000 | 59497000 |
| Tuesday, January 1, 2019 | 336964000 | 65003000 |
| Wednesday, January 1, 2020 | 547851000 | 74506000 |
| Friday, January 1, 2021 | 693716000 | 126006000 |
| Saturday, January 1, 2022 | 891813000 | 126215000 |
| Sunday, January 1, 2023 | 1044071000 | 120161000 |
| Monday, January 1, 2024 | 910408000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
Exelixis has consistently increased its R&D expenses, with a staggering 450% growth from 2014 to 2023. This strategic focus has positioned Exelixis as a leader in the biotech sector, with R&D spending peaking at over $1 billion in 2023. In contrast, Protagonist Therapeutics has shown a more modest increase, with R&D expenses growing by approximately 150% over the same period, reaching around $120 million in 2023.
These figures highlight the differing approaches to innovation and growth, with Exelixis taking a more aggressive stance in its pursuit of groundbreaking therapies.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE